ContextVision AB

ContextVision maintains a strong liquidity position with cash and equivalents of 64.9 million SEK, representing 55% of total assets, and a current ratio of 3.38, well above the industry median. The company's price-to-book ratio of 3.31 and price-to-tangible-book ratio of 3.31 suggest a premium valuation relative to its equity base, supported by a low debt-to-equity ratio of 0.05. Profitability metrics show a return on equity (ROE) of 9.95% and return on assets (ROA) of 7.27%, both exceeding the industry median for AI-based medical imaging firms. Gross margin of 97.6% (33.8 million SEK gross profit on 34.7 million SEK revenue) reflects high-margin software operations, though operating margin of 31.7% (10.98 million SEK operating income) indicates some cost pressures. Geographically, ContextVision's revenue is concentrated in Europe, with 85% of sales derived from the region, and 15% from North America. Segment-wise, the company operates as a single business unit focused on AI imaging software, with no material diversification across product lines. Revenue growth has been modest, with a 4.3% year-over-year increase in revenue to 34.7 million SEK. Outlook for the current fiscal year projects a 6.5% revenue increase, driven by new customer acquisitions in the U.S. and expanded product offerings in oncology imaging. Analysts have issued a single "Hold" recommendation with a mean price target of 3.30 SEK, below the current market price of 3.68 SEK. Risk factors include limited diversification across geographies and product lines, with 85% of revenue from Europe and 100% from a single software platform. The company has no immediate dilution or liquidity risks, with shares outstanding unchanged at 77.4 million and no long-term debt. Recent events include a Q2 2024 earnings report highlighting 12 new hospital contracts in the U.S. and a 20% increase in service revenue.